NCT06230900View on ClinicalTrials.gov

Mass Balance of Orally Administered [14C] (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

April 19, 2025

Study Completion Date

April 19, 2025

Conditions
Energy IntakeEnergy Metabolism
Interventions
OTHER

(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion

COMBINATION_PRODUCT

14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion

Trial Locations (1)

6708PB

Wageningen University and Research, Wageningen

All Listed Sponsors
collaborator

TNO

OTHER

collaborator

Bonumose, Inc.

UNKNOWN

collaborator

Gelderse Vallei Hospital

OTHER

lead

Wageningen University

OTHER

NCT06230900 - Mass Balance of Orally Administered [14C] (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one | Biotech Hunter | Biotech Hunter